Chimerism, Additional Donor
Use to assess donor genotype and compare to recipient genotype prior to allogeneic hematopoietic stem cell transplant. Pretransplant genotyping is required to enable posttransplant chimerism and engraftment monitoring.
New York DOH Approval Status
Lavender (EDTA), pink (K2EDTA), or yellow (ACD solution A or B). OR Bone marrow in lavender (EDTA). OR Buccal brushes from donor.
Transport 2 mL whole blood. (Min: 1 mL). OR Transport 1 mL bone marrow. (Min: 1 mL). OR Transport 2 buccal brushes in a sterile, dry tube. (Min: 2 brushes)
Refrigerated. Also acceptable: Ambient.
Posttransplant results will be compared to pretransplant recipient and donor genotypes, therefore, donor and recipient samples must be obtained and genotyped before the transplant event occurs.
Room Temperature: 1 week; Refrigerated: 1 month; Frozen: Unacceptable
Polymerase Chain Reaction (PCR)/Fragment Analysis
Expected TAT begins at receipt of corresponding Chimerism, Recipient, Pretransplant (3005449) specimen.
Background Information: Chimerism, Additional Donor
Indication: Monitoring for bone marrow transplant patients; interval between bone marrow transplantation and testing is necessary for proper interpretation of results.
Methodology: PCR followed by capillary electrophoresis. Specimens are analyzed using 15 autosomal markers (D8S1179, D21S11, D7S820, CSF1PO, D3S1358, THO1, D13S317, D16S539, D2S1338, D19S433, vWa, TPOX, D18S51, D5S818 and FGA) and one gender marker (amelogenin).
Limitations: Diagnostic errors can occur due to rare sequence variations.
Laboratory Developed Test (LDT)
|Component Test Code*||Component Chart Name||LOINC|
|3005469||Chimerism Ad Don, Specimen|
|3005470||Chimerism Ad Don, Recipient Name|
|3005471||Chimerism Ad Don,InformativeLoci|
|3005472||Chimerism Ad Don, Interpretation|
- Bone Marrow DNA typing
- Chimerism evaluation
- Pre transplant evaluation
- Transplant analysis
- Transplant evaluation